Discover OraSure Technologies' Q2 2025 highlights: strong product launches, expanded leadership, and operational milestones amid market challenges.

The investigational tuberculosis vaccine M72/AS01E-4 has an acceptable safety profile and robust immunogenicity among ...

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Starting in the mid-2010s, the University of Oxford pediatrician and immunologist began working with scientists in the South African province of KwaZulu-Natal, with the aim of tracking several hundred ...

Evidence is growing that some HIV-infected infants, if given antiretroviral drugs early in life, are able to suppress their ...

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

FDA Green-Lights Gilead Sciences’ Groundbreaking HIV Prevention Drug A twice-yearly injection of lenacapavir would offer near-complete protection against the virus, clinical date indicate. More ...

For this study, the researchers used an HIV protein called MD39 as their vaccine antigen, and anchored dozens of these proteins to each alum particle, along with SMNP.

Site-selective modifications of proteins, without compromising their biological activity, are highly sought after due to their critical role in many biomedical applications. Here, we established a ...